Public note

For situational awareness and research transparency. Not medical advice.

Needs resolution

This prediction reached its horizon without auto-resolution. Our synthesis agents are reviewing. Check back, or contribute your assessment.

Novel Pathogen Detectionexpired

XDR Shigella (extensively drug-resistant, resistant to azithromycin + fluoroquinolones + 3GC) will establish sustained community transmission in at least 3 US states within 12 months of CDC's April 2026 emergence report, requiring updated CDC treatment guidance and triggering enhanced surveillance protocols.

System-generated assessment. This assessment remains under review until the stated horizon or until sufficient evidence allows evaluation.

Moderate confidence

Confidence in this assessment

40%

The evidence is meaningful, but there is still material uncertainty. Based on 69 linked evidence items and assessed against Apr 13, 2027.

Assessed through Apr 13, 202769 linked evidence itemsTracking since Apr 13, 2026

How this assessment will be evaluated

The criteria the system uses to determine whether this assessment is borne out by the stated horizon.

Automated

Method

Evidence Match

The condition the system checks for when evaluating this assessment.

Minimum source quality

T1Primary Institutional

Evidence must meet or exceed this credibility tier to count toward evaluation.

Required terms

fluoroquinolonesdrug-resistantazithromycintransmission

Evidence quality mix

Tracking since Apr 13, 2026.

T020

T130

T219

Integrity referencesCryptographic hashes for verification

Registration

Integrity anchor

Brier 0.202

19 resolved novel pathogen detection predictions.

Scope synthesis

The current analyst narrative for this scope.

Open synthesis →

AMR evidence coverage critically degraded this cycle; two hypotheses resolve in 5 days without supporting data; PubMed failure is the primary bottleneck.

Evidence linked to this assessment

69 linked items.

Emergence of Extensively Drug-Resistant Shigellosis — United States, 2011–2023. case

Currently interpreted as supporting evidence for 5 tracked assessments.

10 cases · 16,788 samples

T1https://www.cdc.gov/mmwr/volumes/75/wr/mm7513a1.htm?s_cid=OS_mm7513a1_wsupports

Apr 22, 2026

Emergence of Extensively Drug-Resistant Shigellosis — United States, 2011–2023. case

Currently interpreted as supporting evidence for 5 tracked assessments.

10 cases · 16,788 samples

T1https://www.cdc.gov/mmwr/volumes/75/wr/mm7513a1.htm?s_cid=OS_mm7513a1_w